| Título: | Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns |
| Autores: | Braun, Hannan M. ; Candelario, Jury ; Hanlon, Courtney L. ; Segura, Eddy R. ; Clark, Jesse L. ; Currier, Judith S. ; Lake, Jordan E. |
| Tipo de documento: | texto impreso |
| Editorial: | Mary Ann Liebert Inc., 2017-10-30T14:13:10Z |
| Dimensiones: | application/pdf |
| Nota general: | info:eu-repo/semantics/restrictedAccess |
| Idiomas: | Inglés |
| Palabras clave: | Facultad de Ciencias de la Salud , Pregrado , Artículos científicos , Medicina |
| Resumen: |
El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado. Purpose: Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence. Methods: This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA. Results: Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns. Conclusion: Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration. Revisión por pares |
| En línea: | Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns 2017, 4 (5):371 LGBT Health |
Ejemplares
| Estado |
|---|
| ningún ejemplar |
